Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2021-01-13
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy of crizotinib as induction therapy in participants with
surgically resectable ALK rearrangement, ROS1 rearrangement, or MET exon 14 mutation positive
NSCLC.